Johnson & Johnson Veteran Joins Insulet Leadership as Medtech Firm Files for IPO

On September 17, 2025, according to Reuters, medical device manufacturer Insulet announced a major personnel change on Tuesday: the appointment of Flavia Pease, former executive of Charles River Laboratories, as the company's new Chief Financial Officer and Executive Vice President, replacing Ana Maria Chadwick. The appointment will take effect officially on September 30.

Newly AppointedCFO Background and Personnel Transition

Frevelia Peace has extensive financial experience in the healthcare industry:

• Previously, she worked at Charles River Laboratories for three years;

• Earlier at Johnson & Johnson (Johnson & Johnson) has been deeply engaged for over 20 years, during which he held multiple leadership positions in the medical device business and served as the Vice President of Finance for the Janssen Pharmaceutical division, covering the two core areas of medical devices and pharmaceuticals.

Image source: Flavia Pease LinkedIn account

Notably, Insulet CorporationShe has been in close contact with Insulet's board of directors and audit committee since January 2024. At least two analysts commented, "Her extensive experience in the industry and deep understanding of the company make her an ideal candidate for chief financial officer."

For departing executives,Insulet stated that Anna Maria Chadwick will transition to a senior advisory role to ensure a smooth handover between the old and new teams. Additionally, Charles River Laboratories has initiated the recruitment process for the next Chief Financial Officer, and during the transition period, Michael Knell, the Chief Accounting Officer, will serve as the interim CFO.

Outstanding Performance:

Revenue Growth Exceeds Expectations, Stock Price and Market Value Rise in Tandem

Besides personnel changes,Insulet Also Disclosed Strong Business Growth Signals:

• Quarterly Performance Breakthrough: Early last month (In August 2025, the company announced that its revenue for the second quarter of 2025 reached US$649.1 million, a significant year-over-year increase of 31%, breaking through the US$600 million mark for the first time; the gross margin further improved to 69.7%, with continuous optimization of profitability.

• Q3 and Full-Year Outlook Raised: Thanks to Wearable Insulin Pumps"Omnipod" Gains Large Numbers of New Customers in the U.S. and International Markets; Insulet Anticipates Q3 Revenue Growth to Exceed Previous Forecast of 22%-25%; Management Previously Raised Full-Year 2025 Revenue Growth Guidance to 24%-27%, Demonstrating Confidence in Continued Business Expansion.

• High market recognition: In the pastOver 52 weeks, Insulet's stock price surged 77.8%, significantly outperforming the broader market, with its current market value reaching $22.8 billion (approximately RMB 162.5 billion); all 24 equity analysts unanimously rate it as a "strong buy."

Core Product Advantages and Industry Recognition

The core driver of Insulet's performance growth comes from its star product, the Omnipod insulin pump: This device offers an alternative to traditional insulin pumps for insulin-dependent diabetes patients, completely eliminating the need for multiple daily injections and significantly improving medication convenience. Among its products, the Omnipod 5 device was approved last year for use by both Type 1 and Type 2 diabetes patients, and its approval scope has recently been further expanded, continuously broadening market coverage.

In terms of industry recognition, not long ago, Newsweek and a data companyIn the "2025 Greatest Companies in the U.S." list jointly released by Plant A, Insulet was listed alongside medical giants such as Dexcom, Boston Scientific, Stryker, Abbott, and iRhythm, highlighting its industry status in the medical device field.

Insulet stated that the company plans to disclose more details of the third-quarter performance and update the full-year guidance during the earnings call on November 6; meanwhile, the company reiterated its revenue outlook target for 2025.